An antiviral drug developed by Glenmark Pharmaceuticals boosted the time it takes Covid-19 patients with mild to moderate symptoms to improve their health in a Phase III study.
Favipiravir, a candidate drug for treating the new coronavirus, has produced promising results in early clinical trials in Russia, according to the Russian Direct Investment Fund.
